BioSculpture Technology, Inc. is developing a patented minimally invasive method and device for the endoscopic removal of visceral or “belly” fat, Endoscopic Visceral Lipectomy or “EVL” as a new treatment of obesity, metabolic syndrome and type 2 diabetes mellitus. Three U.S. patents have been allowed on both the method and device and numerous others are pending. BST filed its Form 1-A with the S.E.C. to fund EVL development and commercialization and initiate becoming a public company. Bringing this highly disruptive EVL technology to market is BST’s highest priority. Although safety and efficacy studies are yet to be performed and regulatory approvals obtained, the Company believes EVL has the potential of doing for obesity treatment what LASIK did for vision correction.
BST will convert production to a next generation version of its pneumatic TCAL system, the Airbush® Liposculptor IIE, a sleeker electrical wand. The Company also is developing a single cannula Power Assisted Liposuction (“PAL”) device, the Airbrush® Liposculptor III, the next generation of a tissue aspiration technology our Founder also invented but successfully licensed to UAM, NuMed, Byron Medical, and Mentor.
Below are the the three new products, all of which have been successfully prototyped, but none of which have yet been submitted for regulatory clearance, which this offering will permit the Company to finish developing and bring to market.
| Airbrush® Liposculptor III | Airbrush® Liposculptor IIE | EVL® | ||||||||
 |
 |
 |
||||||||
|
|
|
You must be logged in to post a comment.